Sentinel lymph node biopsy after neo-adjuvant systemic chemotherapy in patients with breast cancer.

摘要

The aim of neo-adjuvant systemic chemotherapy in the management of breast is to obtain freedom from disease and prolong survival of breast cancer patients (1). The data shown by the 9 years follow-up of the NSABP-18 and 5 years follow-up of the NSABP B-27 trials did not demonstrate a significant difference in overall survival relating to all patients who received neo-adjuvant systemic therapy compared with those who received adjuvant chemotherapy (2). Nevertheless, responding to the neo-adjuvant chemotherapy and decreasing the size of the primary tumor has demonstrated to increase the rate of breast conservation procedures but not the overall survival (3,4).